Locally Advanced NSCLC Treated With Radiochemotherapy: Phase 2 Study on the Value of a Stereotactic Boost
This is a monocentric, non-randomized, open-label, superiority phase II clinical investigation evaluating the efficacy of additional Cyberknife irradiation after a doublet of Platinum Salts-based chemotherapy and concomitant radiotherapy in patients with locally advanced non-small cell lung carcinoma (NSCLC), with an interim analysis.
• Patients aged 18 years old or more
• ECOG 0 to 2
• Histologically proven non-small cell lung cancer
• Stage III non-metastatic tumor, not allowing for immediate surgery
• Volume(s) on the evaluation scan after neoadjuvant treatment meeting the following criteria:
‣ 1 to 3 target volumes of less than 5 cm in greatest diameter
⁃ And enabling additional irradiation to be carried out in compliance with the manufacturer requirements and with the doses delivered to the organs at risk (OAR/fractions) defined in appendix 2
• Patients who have received a Taxcis treatment consisting in 2 cycles of induction chemotherapy (platinium-based doublet) and then at least 40 Gy of irradiation in combination with at least 2 cycles of concomitant chemotherapy (platinium-based doublet)
• No contraindication to implantable venous devices (IVDs)
• Patient who has read the patient information note and signed the consent form
• If applicable, negative pregnancy test\*
⁃ Eligible for National Health Insurance in France